BR112017016084A2 - composição e método para o tratamento da doença veno-oclusiva hepática - Google Patents
composição e método para o tratamento da doença veno-oclusiva hepáticaInfo
- Publication number
- BR112017016084A2 BR112017016084A2 BR112017016084A BR112017016084A BR112017016084A2 BR 112017016084 A2 BR112017016084 A2 BR 112017016084A2 BR 112017016084 A BR112017016084 A BR 112017016084A BR 112017016084 A BR112017016084 A BR 112017016084A BR 112017016084 A2 BR112017016084 A2 BR 112017016084A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- composition
- occlusive disease
- hepatic veno
- veno
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
?composição e método para o tratamento da doença veno-oclusiva hepática?. a presente invenção se refere a uma composição compreendendo um análogo, um derivado ou um sal farmaceuticamente aceitável de prostaciclina para utilização na prevenção ou no tratamento de síndrome da obstrução sinusoidal e/ou doença veno-oclusiva hepática (dvo).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15152665 | 2015-01-27 | ||
PCT/EP2016/051675 WO2016120311A1 (en) | 2015-01-27 | 2016-01-27 | Composition for the treatment of hepatic veno-occlusive disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017016084A2 true BR112017016084A2 (pt) | 2018-03-27 |
Family
ID=52394992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017016084A BR112017016084A2 (pt) | 2015-01-27 | 2016-01-27 | composição e método para o tratamento da doença veno-oclusiva hepática |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180021347A1 (pt) |
EP (1) | EP3250289A1 (pt) |
JP (1) | JP2018503654A (pt) |
KR (1) | KR20170106360A (pt) |
CN (1) | CN107592811A (pt) |
AU (1) | AU2016212091A1 (pt) |
BR (1) | BR112017016084A2 (pt) |
CA (1) | CA2973147A1 (pt) |
CL (1) | CL2017001904A1 (pt) |
EA (1) | EA201791696A1 (pt) |
IL (1) | IL253390A0 (pt) |
SG (1) | SG11201705809QA (pt) |
WO (1) | WO2016120311A1 (pt) |
ZA (1) | ZA201704957B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5859433B2 (ja) | 2009-06-12 | 2016-02-10 | マンカインド コーポレイション | 規定された比表面積を有するジケトピペラジン微粒子 |
EP4137127A1 (en) | 2013-01-11 | 2023-02-22 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
KR102391750B1 (ko) | 2013-03-15 | 2022-04-28 | 맨카인드 코포레이션 | 미세결정성 디케토피페라진 조성물 및 방법 |
JP6491658B2 (ja) | 2013-07-18 | 2019-03-27 | マンカインド コーポレイション | 熱安定性乾燥粉末医薬組成物及び方法 |
US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
EP3498283A1 (en) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidic derivatives of treprostinil |
MX2021008943A (es) * | 2019-01-25 | 2021-11-04 | Janssen Pharmaceutica Nv | Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos. |
-
2016
- 2016-01-27 CN CN201680010849.4A patent/CN107592811A/zh active Pending
- 2016-01-27 CA CA2973147A patent/CA2973147A1/en not_active Abandoned
- 2016-01-27 EP EP16701551.0A patent/EP3250289A1/en not_active Withdrawn
- 2016-01-27 SG SG11201705809QA patent/SG11201705809QA/en unknown
- 2016-01-27 BR BR112017016084A patent/BR112017016084A2/pt not_active Application Discontinuation
- 2016-01-27 AU AU2016212091A patent/AU2016212091A1/en not_active Abandoned
- 2016-01-27 WO PCT/EP2016/051675 patent/WO2016120311A1/en active Application Filing
- 2016-01-27 EA EA201791696A patent/EA201791696A1/ru unknown
- 2016-01-27 JP JP2017539662A patent/JP2018503654A/ja active Pending
- 2016-01-27 KR KR1020177021201A patent/KR20170106360A/ko unknown
- 2016-01-27 US US15/547,060 patent/US20180021347A1/en not_active Abandoned
-
2017
- 2017-07-10 IL IL253390A patent/IL253390A0/en unknown
- 2017-07-20 ZA ZA2017/04957A patent/ZA201704957B/en unknown
- 2017-07-25 CL CL2017001904A patent/CL2017001904A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170106360A (ko) | 2017-09-20 |
SG11201705809QA (en) | 2017-08-30 |
AU2016212091A1 (en) | 2017-08-03 |
CA2973147A1 (en) | 2016-08-04 |
EA201791696A1 (ru) | 2017-11-30 |
WO2016120311A1 (en) | 2016-08-04 |
JP2018503654A (ja) | 2018-02-08 |
EP3250289A1 (en) | 2017-12-06 |
CL2017001904A1 (es) | 2018-03-23 |
ZA201704957B (en) | 2018-12-19 |
CN107592811A (zh) | 2018-01-16 |
US20180021347A1 (en) | 2018-01-25 |
IL253390A0 (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017016084A2 (pt) | composição e método para o tratamento da doença veno-oclusiva hepática | |
BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
BR112015023349A2 (pt) | composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio | |
BR112016022593A2 (pt) | composições e métodos para modular a expressão do fator b do complemento | |
SV2018005643A (es) | Composiciones de insulina de rapida accion | |
MX2015015518A (es) | Metodos y composiciones para el tratamiento del cancer. | |
DOP2016000253A (es) | Nuevos compuestos | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
MX2020001256A (es) | Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos. | |
MX2017004760A (es) | Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma. | |
DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
BR112015016033A2 (pt) | composições e métodos para tratamento de infecções por bactérias | |
BR112018069900A2 (pt) | composição antimicrobiana, método de limpeza ou desinfecção de uma superfície e uso de um complexo fosfolipídico catiônico | |
EP3292872A4 (en) | COMPOSITION FOR THE TREATMENT OR PREVENTION OF INFECTIOUS INFLAMMATORY DISEASES OR COMPOSITION FOR IMMUNE REINFORCEMENT WITH TRYPTOPHANYL TRNA SYNTHETASE AS AN ACTIVE AGENT | |
WO2015001541A3 (en) | Pharmaceutical film composition | |
BR112018004249A2 (pt) | composto, e, composição para prevenção ou tratamento de doenças trombóticas. | |
CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
BR112018007374A2 (pt) | composição farmacêutica | |
MX2018013203A (es) | Ciclodextrinas como procoagulantes. | |
BR112018007651A2 (pt) | composição de limpeza antimicrobiana, método para a desinfecção de uma superfície e utilização de uma composição | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
BR112017011591A2 (pt) | composição de liberação prolongada estável, processo para a preparação da composição de liberação prolongada | |
BR112016019002A2 (pt) | composições para a prevenção e/ou o tratamento de patologias associadas a alfa-glicosidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |